Invesaro

Stocks SLXN Earnings

Earnings

Silexion Therapeutics Corp (SLXN) earnings

Quarterly results of Silexion Therapeutics Corp as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when SLXN files with the SEC.

Latest quarter: Q2 FY2026

In Q2 FY2026 (ended June 30, 2026) Silexion Therapeutics Corp reported revenue of - and a net loss of $3.6M.

Diluted earnings per share were $5.17 (-88% on the same quarter a year earlier).

Filed with the SEC on August 14, 2026.

Net income by quarter
Q3 24: -$11.9M -$11.9M Q3 24Q4 24: -$1.7M -$1.7M Q4 24Q1 25: -$1.7M -$1.7M Q1 25Q2 25: -$2.5M -$2.5M Q2 25Q3 25: -$3.3M -$3.3M Q3 25Q4 25: -$4.4M -$4.4M Q4 25Q1 26: -$2.7M -$2.7M Q1 26Q2 26: -$3.6M -$3.6M Q2 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q2 FY2026June 30, 2026---$3.6M$5.17
Q1 FY2026March 31, 2026---$2.7M$0.85
Q4 FY2025December 31, 2025---$4.4M-
Q3 FY2025September 30, 2025---$3.3M$2.88
Q2 FY2025June 30, 2025---$2.5M$43.19
Q1 FY2025March 31, 2025---$1.7M$3.84
Q4 FY2024December 31, 2024---$1.7M-
Q3 FY2024September 30, 2024---$11.9M$274.25

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

Get an email when SLXN reports

Follow SLXN and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when SLXN files with the SEC.

Source: quarterly figures Silexion Therapeutics Corp tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Silexion Therapeutics Corp